Trial Profile
Investigator initiated Phase II Study of Gedatolisib in Advanced Recurrent Small-Cell Lung Cancer Patients harboring Molecular Alterations in PI3K/AKT/mTOR Pathway
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Aug 2020
Price :
$35
*
At a glance
- Drugs Gedatolisib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms EAGLE-PAT; LC-SCRUM-Japan
- 12 Aug 2020 Status changed from suspended to discontinued.
- 20 Jul 2020 Status changed from active, no longer recruiting to suspended.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology